Amicus Therapeutics, Inc. (FOLD)

Over the last 12 months, Amicus Therapeutics' stock price has increased by 109.94%. Key events impacting the stock include strong Q3 2025 and full-year 2025 financial results, a proposed acquisition by BioMarin expected in Q2 2026, presentations at the 22nd Annual WORLDSymposium 2026, investigations regarding shareholder deals, and insider selling.

Based on available information, there is no explicit mention of significant demand seasonality for Amicus Therapeutics' products and services. The company consistently reports strong and growing demand for both Galafold and Pombiliti + Opfolda, suggesting a steady and increasing demand rather than seasonal fluctuations.

Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing, and delivering medicines for rare diseases, particularly lysosomal storage disorders. Their lead product is Galafold (migalastat) for Fabry disease, and they also market Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) for late-onset Pompe disease. The company is advancing a pipeline of gene therapies and combination therapies.

Amicus Therapeutics is headquartered in Princeton, New Jersey, and has a global presence with products approved and commercialized in the United States, European Union, and other territories. A significant portion of revenue comes from outside the U.S. The company has expanded its global launch progress for Pombiliti and Opfolda, securing reimbursement in additional countries.

Amicus Therapeutics maintains a brand reputation as a patient-dedicated global biotechnology company focused on developing and delivering transformative medicines for people living with rare diseases. The company's reputation has been affected by continued strong performance and pipeline advancement, strategic partnerships and market expansion, movement towards profitability, and shareholder investigations.

Amicus Therapeutics has a mixed ownership structure. Institutional investors own approximately 69.48% to 89.72% of the stock, with major holders including BlackRock, Inc. and Vanguard Group Inc. Insiders own approximately 1.01% to 51.13% of the stock, while public companies and individual investors hold around 9.27% to 20.24%. Perceptive Advisors LLC is the largest individual shareholder.